Lee Jiau Jiunn, CEO, AmMetLife
As the Government prepares to transition Malaysia into the endemic phase of COVID-19, AmMetLife Insurance Berhad (AmMetLife) will expand its support to new and existing medical plan customers by adding a COVID-19 Hospitalisation Reimbursement Benefit. This benefit will form part of the company’s COVID-19 Fund that has been increased to RM5 million from RM1 million.
As part of its commitment to protecting the health and well-being of its customers, AmMetLife will reimburse medical expenses received as a *Category three, four or five COVID-19 patient at a Ministry of Health designated hospital. The coverage period is effective from 1 September 2021 until 31 December 2021 or when the total payout for the AmMetLife COVID-19 Fund reaches RM5 million, whichever is earlier. All claims payable for this benefit will be on a first-come-first-served basis.
“The pandemic has been an extremely difficult time for all of us and we remain committed to supporting our customers with coverage to help them live confidently. We hope the launch of our COVID-19 Hospitalisation Reimbursement Benefit will help alleviate some of our customers’ financial worry,” said Lee Jiau Jiunn, CEO, AmMetLife.
Since the onset of COVID-19, AmMetLife has introduced various support programs to help its customers navigate through the health crisis. In support of the National COVID-19 Immunisation Programme, a Post-COVID-19 Post-COVID-19 vaccination coverage vaccination coverage was announced in May 2021 for AmMetLife’s existing and new medical plan customers.
Please visit www.ammetlife.com or www.ammetlifetakaful.com for more information.
*Clinical stage of confirmed COVID-19 patients as categorised by the Ministry of Health
